ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 89

A Longitudinal Genome-Wide Association Study of Anti-Tumor Necrosis Factor Response Among Japanese Patients with Rheumatoid Arthritis

Kyoko Honne1, Ingileif Hallgrimsdottir2, Chunsen Wu3, Ronnie Sebro4, Nicholas Jewell2, Takeo Sakurai5, Masahiro Iwamoto6, Seiji Minota6 and Damini Jawaheer7, 1Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, 2UC Berkeley, Berkeley, CA, 3University of Southern Denmark, Odense, Denmark, 4University of Pennsylvania, Philadelphia, PA, 5Inoue Hospital, Takasaki, Japan, 6Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, 7Children's Hospital Oakland Research Institute, Oakland, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: anti-TNF therapy, biomarkers and rheumatoid arthritis (RA), GWAS

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Genetics, Genomics and Proteomics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Studies of patients with rheumatoid arthritis (RA) to identify genetic biomarkers of anti-tumor necrosis factor (TNF) response have been conducted mostly in Caucasian populations. These studies have used anti-TNF response at a single follow up time point as the phenotype with which single nucleotide polymorphisms (SNP) associations have been tested. There has been little overlap in findings across studies. To identify genetic biomarkers of anti-TNF response among Japanese RA patients, we have performed a genome-wide association study (GWAS) using response at 2 follow up time-points for a more reliable clinical phenotype over time.

Methods: Disease Activity Scores based on 28 joint counts and C-reactive protein (DAS28) were assessed at baseline (before initial therapy), and after 3 and 6 months in 487 Japanese RA patients starting anti-TNF therapy for the first time or switching to a new anti-TNF agent. A genome-wide panel of 1,133,484 SNPs was genotyped and additional SNPs were imputed. Using change in DAS28 scores from baseline (ΔDAS28) at both 3 and 6 months as the response phenotype, a longitudinal genome-wide association analysis was conducted using Generalized Estimating Equations (GEE) models to accommodate the repeated measures of the outcome, adjusting for baseline DAS28, time since initiation of therapy, type of anti-TNF agent and concomitant methotrexate.

Results: A total of 4,253,138 autosomal SNPs passed quality thresholds for association analysis. Suggestive evidence of association (p<1×10-6) with ΔDAS28 was observed at 3 chromosomal regions (6q15: rs284515, p=6.6×10-7; 6q27: rs75908454, p=6.3×10-7 and 10q25.3: rs1679568, p=8.1×10-7), extending to numerous SNPs in linkage disequilibrium (LD) with the index SNPs across each region. Potential candidate genes in these regions include MAP3K7 (6q15) a key player in TNFα-mediated inflammatory pathway signaling, GFRA1 (10q25.3) which was associated with anti-TNF response in an independent study, and WDR27 (6q27).

Conclusion: In this first GWAS of anti-TNF response among Japanese RA patients using a longitudinal analysis approach, three genomic regions demonstrated suggestive association with response to anti-TNF therapy. Using more than one assessment of response enhanced the power to detect these associations.


Disclosure: K. Honne, None; I. Hallgrimsdottir, None; C. Wu, None; R. Sebro, None; N. Jewell, None; T. Sakurai, None; M. Iwamoto, Astellas Pharma, 8,Takeda Phamaceutical, 8; S. Minota, Astellas, 2,Pfizer Inc, 2,Essai, 2,AbbVie, 2,Mitsubishi-Tanabe, 2,Takeda, 2,Chugai, 7; D. Jawaheer, None.

To cite this abstract in AMA style:

Honne K, Hallgrimsdottir I, Wu C, Sebro R, Jewell N, Sakurai T, Iwamoto M, Minota S, Jawaheer D. A Longitudinal Genome-Wide Association Study of Anti-Tumor Necrosis Factor Response Among Japanese Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/a-longitudinal-genome-wide-association-study-of-anti-tumor-necrosis-factor-response-among-japanese-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-longitudinal-genome-wide-association-study-of-anti-tumor-necrosis-factor-response-among-japanese-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology